HomeCompareCTHRQ vs MRK

CTHRQ vs MRK: Dividend Comparison 2026

CTHRQ yields 15209.13% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTHRQ wins by $3473564864705308672.00M in total portfolio value
10 years
CTHRQ
CTHRQ
● Live price
15209.13%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3473564864705308672.00M
Annual income
$3,429,211,375,591,879,600,000,000.00
Full CTHRQ calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CTHRQ vs MRK

📍 CTHRQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTHRQMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTHRQ + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTHRQ pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTHRQ
Annual income on $10K today (after 15% tax)
$1,292,775.67/yr
After 10yr DRIP, annual income (after tax)
$2,914,829,669,253,097,500,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CTHRQ beats the other by $2,914,829,669,253,097,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTHRQ + MRK for your $10,000?

CTHRQ: 50%MRK: 50%
100% MRK50/50100% CTHRQ
Portfolio after 10yr
$1736782432352654336.00M
Annual income
$1,714,605,687,795,939,800,000,000.00/yr
Blended yield
98.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CTHRQ
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-3.9
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTHRQ buys
0
MRK buys
0
No recent congressional trades found for CTHRQ or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTHRQMRK
Forward yield15209.13%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3473564864705308672.00M$56.8K
Annual income after 10y$3,429,211,375,591,879,600,000,000.00$9,798.13
Total dividends collected$3470630504683258880.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CTHRQ vs MRK ($10,000, DRIP)

YearCTHRQ PortfolioCTHRQ Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,531,613$1,520,912.55$11,206$366.19+$1.52MCTHRQ
2$219,344,315$217,705,489.86$12,650$502.35+$219.33MCTHRQ
3$29,372,921,960$29,138,223,543.14$14,407$694.19+$29372.91MCTHRQ
4$3,678,129,229,453$3,646,700,202,954.87$16,585$967.82+$3678129.21MCTHRQ
5$430,707,792,715,276$426,772,194,439,761.75$19,342$1,363.89+$430707792.70MCTHRQ
6$47,166,363,589,446,140$46,705,506,251,240,810.00$22,913$1,947.19+$47166363589.42MCTHRQ
7$4,830,534,868,893,136,000$4,780,066,859,852,428,000.00$27,662$2,823.89+$4830534868893.11MCTHRQ
8$462,691,766,266,782,700,000$457,523,093,957,067,000,000.00$34,159$4,173.35+$462691766266782.63MCTHRQ
9$41,451,858,984,513,220,000,000$40,956,778,794,607,770,000,000.00$43,337$6,308.80+$41451858984513224.00MCTHRQ
10$3,473,564,864,705,309,000,000,000$3,429,211,375,591,879,600,000,000.00$56,776$9,798.13+$3473564864705308672.00MCTHRQ

CTHRQ vs MRK: Complete Analysis 2026

CTHRQStock

Charles & Colvard, Ltd. operates as a fine jewelry company in the United States and internationally. It operates through two segments: Online Channels and Traditional. The company manufactures, markets, and distributes moissanite jewels and finished moissanite jewelry under the Charles & Colvard Created Moissanite brand; and premium moissanite gemstones under the Forever One brand name. It also markets and distributes lab grown diamonds and finished jewelry with lab grown diamonds under the Caydia brand. It sells its products at wholesale prices to distributors, manufacturers, retailers, and designers; and to end-consumers at retail prices through charlesandcolvard.com and moissaniteoutlet.com, third-party online marketplaces, drop-ship, and other e-commerce outlets, as well as through Charles & Colvard Signature Showroom and charlesandcolvarddirect.com for wholesale and retail customers. Charles & Colvard, Ltd. was incorporated in 1995 and is headquartered in Morrisville, North Carolina. On March 2, 2026, Charles & Colvard, Ltd. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Full CTHRQ Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CTHRQ vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTHRQ vs SCHDCTHRQ vs JEPICTHRQ vs OCTHRQ vs KOCTHRQ vs MAINCTHRQ vs JNJCTHRQ vs ABBVCTHRQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.